Clinical trial
A Parallel-group Prevention, Phase II, Partially Blinded, Multi-stage Study to Investigate the Immunogenicity and Safety of Pentavalent Meningococcal ABCYW Vaccine Formulations Compared With Licensed Meningococcal Vaccines When Administered Alone in Healthy Children (2 to 9 Years of Age) or Concomitantly With Routine Pediatric Vaccines in Toddlers (12 to 15 Months of Age) and Infants (2 Months of Age).
NCT06647407 is registered in ClinicalTrials.gov with Sanofi Pasteur, a Sanofi Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Parallel-group Prevention, Phase II, Partially Blinded, Multi-stage Study to Investigate the Immunogenicity and Safety of Pentavalent Meningococcal ABCYW Vaccine Formulations Compared With Licensed Meningococcal Vaccines When Administered Alone in Healthy Children (2 to 9 Years of Age) or Concomitantly With Routine Pediatric Vaccines in Toddlers (12 to 15 Months of Age) and Infants (2 Months of Age).
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Phase
- Phase 1/2
- Overall status
- Active, not recruiting
- Start date
- November 5, 2024
- Completion date
- May 17, 2027
- Enrollment
- 750 (estimated)
- Sites
- 39
Conditions
As the registry lists them; a condition with its own page is linked.
healthy volunteers, meningococcal immunization